ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
Berns K, Caumanns JJ, Hijmans EM, Gennissen AMC, Severson TM, Evers B, Wisman GBA, Jan Meersma G, Lieftink C, Beijersbergen RL, Itamochi H, van der Zee AGJ, de Jong S, Bernards R.
Berns K, et al.
Oncogene. 2018 Aug;37(33):4611-4625. doi: 10.1038/s41388-018-0300-6. Epub 2018 May 15.
Oncogene. 2018.
PMID: 29760405
Free PMC article.